CompletedPhase IInterventional

Phase I Study: Quotient Code QSC303166

This is an early-stage study, known as Phase I, for a new treatment called QSC303166. In these types of studies, researchers are mainly looking at whether a new medicine is safe and doesn't cause too many side effects in people. They also start to figure out the right dosage. At this moment, the full details about what specific health conditions this treatment is for, or exactly what the treatment involves, aren't publicly available. This is a common practice for early research to protect future discoveries. All the information will be fully published within 30 months after the study has ended, offering a complete picture of the findings.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Novartis Pharmaceuticals UK Limited

Enrolment target

Start

05 Sep 2025

Estimated completion

30 Mar 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study, known by its code QSC303166, is what's called a 'Phase I' clinical trial. Think of clinical trials as steps in developing new medicines. Phase I is the very first step where a new treatment is given to people. The main goal at this stage isn't to cure a disease, but rather to see if the new medicine is safe for people to take and to understand how the body handles it. Researchers also try to work out the best dose.

Because this is such an early stage of research, many of the specific details about the treatment itself, such as what it's for or exactly how it works, are not yet public. This isn't unusual. Companies sometimes keep these details private for a time to protect their research, especially when it's very new and promising. This helps them secure patents and continue their development without others immediately copying their work.

Even though the full specifics are currently kept private, rest assured that all clinical trials, even those with deferred information, must follow strict ethical and safety guidelines. The information will eventually be made public. All the detailed findings from this study will be published and available for everyone to see within 30 months after the study officially finishes. This ensures transparency in the long run.

Key takeaways

QSC303166 is an early-stage (Phase I) study for a new treatment.
The main goal is to check for safety and how the body handles the medicine.
Full study details are currently private but will be published within 30 months after the study ends.
Specific eligibility rules for joining are not yet public.
Participation would involve regular visits and careful monitoring, similar to other early trials.

Who may be eligible?

At this time, the exact health conditions or specific criteria for who can or cannot take part in this study are not publicly available. This information is typically shared once the study details are fully published.

However, in general, for any clinical trial, the research team will have very clear rules about who can join. These rules are put in place to ensure patient safety and to make sure the study results are as accurate as possible. They might include things like your age, other health conditions you have, or medicines you are currently taking.

Even though the specific details for QSC303166 are not yet public, all individuals, regardless of age or gender, could potentially be considered for this type of early-stage trial once the full eligibility criteria are released.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do I meet the specific health requirements for taking part when they are released?
Am I within the specified age range?
Am I able to commit to the required number of clinic visits?
Am I comfortable with the experimental nature of a Phase I trial?
Do I understand that this trial aims primarily for safety data, not necessarily direct personal health benefit?
Am I prepared for potential unknown side effects from a new treatment?

Answer every question to see your result.

What does participation involve?

Since the full details of this study aren't yet public, we don't have specific information about what taking part would involve. However, in a typical Phase I study like this, you might expect:

* **Regular Visits:** You would likely need to attend a clinic or hospital regularly for check-ups, blood tests, and to receive the study treatment. * **Assessments:** These visits would include various tests to monitor your health and see how your body is reacting to the new medicine. This could involve physical examinations, vital signs (like blood pressure and heart rate), and detailed scans. * **Medication:** You would be given the new study medicine, likely under close supervision. * **Follow-up:** Even after you stop taking the medicine, there would be follow-up appointments to make sure you are well and to track any longer-term effects. * **Total Duration:** The total time you would be involved in the study can vary greatly, but Phase I studies often last from a few weeks to several months, depending on the treatment being tested.

Potential risks and benefits

Because the full details of this particular study are not yet public, we can only talk about potential benefits and risks in general terms for Phase I trials. A potential benefit could be access to a brand-new treatment that isn't available elsewhere, which might help advance medical science. However, the primary aim of these early studies is safety, not direct health improvement for participants. There are always potential risks with any new medicine, including unexpected side effects that range from mild to serious. Before joining, you would receive a detailed consent form explaining all known risks. Remember, you would always have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is a Phase I study?

It's the first step in testing a new medicine in people. Researchers mainly check if it's safe to use and how the body handles it.

Why can't I see all the study details now?

The full information is being kept private for a while to protect the research, which is common for very new treatments. It will be made public later.

When will the full study details be available?

All the details will be published within 30 months after the study officially finishes.

Who can take part in this study?

The specific eligibility rules aren't public yet. All clinical trials have clear guidelines on who can and can't join to ensure safety and good results.

Is this medicine available to the public?

No, it's a new experimental medicine being tested. It's not available for general use outside of the study.

How to find out more

. Novartis Study Director

novartis.email@novartis.com +41 61 324 11 11 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.